Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

For 2025, Regeneron reiterated its projection for research-and-development spending in a range between $5.56 billion and $5.795 billion. The company cut the top end of its forecasted range for 2025 ...

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...